NCT/Study#

NCT04943900 /

CA102-003

Phase 1 Study of BMS-986416 (TGF-b Inhibitor) Alone and in Combination with Nivolumab in Advanced Malignant Tumors.

Phase 1 Study of BMS-986416 (TGF-b Inhibitor) Alone and in Combination with Nivolumab in Advanced Malignant Tumors.

DISEASE GROUP:
Phase 1
current phase:
Phase I
STUDY STATUS:
Accepting Patients
Location:
Hackensack, NJ
For More information: